The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

NCT01618162 · Completed

Last updated 2026-05-28

This clinical trial tested whether adding insulin degludec/liraglutide to existing diabetes medications helps lower blood sugar levels in adults with type 2 diabetes who are not well-controlled on sulfonylurea, with or without metformin.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 435 people

Who can join Ages 18+ · all sexes

Timeline Started 2012-08 · est. completion 2013-10

Where 87 sites · Bulgaria, Canada, Germany, India, Israel, Puerto Rico, Turkey (Türkiye), United States

What this study is testing ClinicalTrials.gov NCT01618162 ↗

Description as written by the study sponsor.

This trial is conducted in Asia, Europe and the United States of America (USA). The aim of this trial is to investigate the efficacy and safety of insulin degludec/liraglutide in insulin naïve subjects inadequately controlled with SU (sulphonylurea) alone or in combination with metformin. All subjects will continue their pre-trial SU treatment with or without metformin treatment without changing the frequency or dose throughout the trial.

Treatments tested

insulin degludec/liraglutide Drug

Injected subcutaneously (under the skin) once daily. Dose individually adjusted.
placebo Drug

Injected subcutaneously (under the skin) once daily.

Main thing measured	Change in Glycosylated Haemoglobin (HbA1c)
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01618162 ↗